Balyasny Asset Management
KRON

Balyasny Asset Management’s Kronos Bio KRON Stock Holding History

Balyasny Asset Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,509
Closed -$18.1K – 2512
2023
Q2 		$18.1K Buy
+10,509
New +$16.7K ﹤0.01% 2159

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's KRON Position: Q3 2023 in Review

Balyasny Asset Management sold out of Kronos Bio (KRON) in Q3 2023, closing a stake of 10,509 shares — an estimated $18.1K sold.

Balyasny Asset Management first reported a position in KRON in Q2 2023 and held it in 1 quarter. The position peaked at $18.1K in Q2 2023. 63 funds tracked by Wall St. Rank hold KRON as of Q3 2023.

  • Balyasny Asset Management reported no remaining Kronos Bio position as of Q3 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 10,509 Kronos Bio shares in Q3 2023, an estimated $18.1K.
  • Balyasny Asset Management first reported a position in Kronos Bio in Q2 2023 and held it in 1 quarter.
  • Balyasny Asset Management's Kronos Bio position peaked at $18.1K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.